

For qualified investors only



**First State Stewart Asia**

**– China Equities**

Client Update

July 2018

# FIRST STATE STEWART ASIA – CHINA EQUITIES

## 40<sup>th</sup> anniversary of reforms

It has been 40 years since Mr Deng Xiaoping embarked on his ambitious market-based reform program and began to open up China's economy. Since then, China has been transformed; while there have been stops and starts on the way, China was one of the fastest-growing countries in the world over the past four decades, averaging 10% growth a year.

Today, China is the second-largest economy in the world in terms of nominal GDP and is forecast to overtake the United States on this measure within the next decade. In terms of purchasing power, which takes into consideration the relative cost of local goods and services, China has already surpassed the US – perhaps unsurprising due to the relative size of the two nations' populations.

Chinese consumers are earning more and spending more, both at home and overseas. Rising incomes and consumption upgrading (trading up to premium quality products) should continue to drive China's economic growth in 2018, despite concerns of a slowdown. Within our China portfolios, this is a key investment theme underpinning many of our long-term holdings.

However, there is more to be done. At this year's annual Boao Forum (the Asian equivalent to the World Economic Forum in Davos), President Xi Jinping delivered a keynote speech about China's mission to "continue to improve itself through reform", in order to "meet its people's aspirations for development, innovation and a better life".

We have been following the reforms closely. Since 2015, two-thirds of China's central state-owned enterprises (SOEs) have been restructured, listed or have introduced some kind of shareholder reform. Stronger SOEs have swallowed up weaker ones, non-

performing assets have been sold and inefficient 'zombie enterprises' – those that have been loss-making for years – have been allowed to go out of business.

Despite China's progress towards a market-based economy, companies or sectors at the core of domestic economic security or deemed to be of national importance will remain under some level of state-ownership and the Chinese government is to play a bigger role in the economy than ever before. The intention is to consolidate power within a few home-grown corporate giants, so that these mega-entities can compete with international players.

Though this seems to be a setback, the emphasis on bringing market-oriented reforms to the state-owned sector by way of mixed ownership is a positive step. This way, the private sector can introduce corporate governance best practice, influence decision-making, enhance efficiencies and improve shareholder returns, while the state retains a level of beneficial interest.

The results are starting to show. Market consolidation has driven cost savings and other synergies, while asset sales have bumped up productivity. Last year, China's central SOEs – with total combined assets of almost USD9 trillion – reported record high profits and an average of 15% profit growth, the highest in five years.

We believe SOE reform is an important step towards improving shareholder returns in the Chinese equity market. Some companies that have adopted market-based practices have seen success, such as **Wanhua Chemical**, **Gree Electric** and **CSPC Pharmaceutical\***, which we highlight below. We also note a few of the more recent SOE restructurings and our expectations for these companies.

## Mixed ownership models

Mixed ownership reform, which injects private capital into state-owned companies (and in many cases reduces government ownership to a minority interest), needs to be followed by equity ownership and incentive programs to align management with shareholders. Both steps are necessary to bring state-owned enterprises in line with private companies.

Some SOEs, such as **China Unicom**, implemented both steps at almost the same time. In August 2017, Unicom added 14 strategic investors – which included, among others, technology giants Tencent and Alibaba, industry verticals Suning and Didi, as well as insurance company China Life. Following the reform, strategic investors held 35% of the company, the government held 37% and 25% was in free float. The remaining shares, representing approximately 2.7% of the enlarged capital, was allotted as employee incentives.

Others, such as **Yunnan Baiyao** and **Tsingtao Brewery**, have, as yet, taken only the first step towards reform. In December 2016, the parent group of Yunnan Baiyao, a leading Traditional Chinese Medicine (TCM) brand well-known for its powdered herbal haemostatic medicine, restructured its share capital. New Huadu Industrial Group, a private conglomerate with business interests in supermarkets and retail shopping malls, was brought in as a 50-50 shareholder. In 2017, Jiangsu Yuyue, a medical equipment manufacturer, became an additional strategic investor, with New Huadu and SASAC<sup>1</sup> each reducing their holdings to 45%.

Baiyao's parent's five-member board of directors now comprises two members from SASAC, two from New Huadu and one from Yuyue, which should serve as a more effective decision-making process

1 SASAC – the State-owned Assets Supervision and Administration Commission of the State Council – is one of the most powerful agencies in China. It is responsible for managing China's State-Owned Enterprises (SOEs) and has been instrumental in pushing forward SOE reforms. All mergers and asset sales in the SOE sector must be approved by SASAC.

\*For illustrative purposes only. Reference to the names of each company mentioned in this communication is merely for explaining the investment strategy, and should not be construed as investment advice or investment recommendation of those companies. Companies mentioned herein may or may not form part of the holdings of First State Investments.

and allow Baiyao to introduce management incentives. An employee stock ownership plan (ESOP) is expected to be launched before the end of the year.

Meanwhile, Tsingtao Brewery, one of the oldest brewers in China and perhaps the only Chinese beer with a well-known brand outside of its home market, introduced Fosun International as a strategic shareholder in December 2017. Fosun bought an 18% stake in Tsingtao Brewery from Asahi Group Holdings, the Japanese beer maker. The unlisted state-owned parent company of Tsingtao Brewery bought Asahi's remaining 1.99% stake and remains the largest shareholder.

## Signs of a turnaround at COFCO

At the central SASAC level, one of the largest state-owned enterprises is **China National Cereals, Oils and Foodstuffs Corporation (COFCO)**, a domestic leader in grains, oils and foodstuffs.

In 2016, a merger between COFCO and Chinatex, ranked first and third in China's agro-grain sector, kick-started an ambitious reform program. COFCO subsequently reorganised itself into an asset manager overseeing 18 specialised companies – each responsible for its own business operations, management appointments and staffing decisions. COFCO HQ would appoint directors to the boards of each subsidiary company but would no longer be involved in the day-to-day operations.

The goal was to make COFCO more commercial and competitive; and improve returns and profitability. Importantly, a stronger COFCO would ensure that China's international grain and food supply would be more secure for the future.

Since the restructuring, COFCO Group's profits have grown significantly. Its underlying listed group companies – **China Foods, China Agri-Industries, CPMC Holdings** and **China Mengniu Dairy** – have all reported notable improvements.

China Foods reorganised its business to focus on beverages, disposing of its consumer-pack edible oil business to China Agri-Industries. Resource consolidation resulted in synergistic cost savings and, earlier this year in March, both China Foods and China Agri-Industries announced record high profits due to improved operating efficiencies.

At CPMC Holdings, the management have executed as promised, cutting costs and consolidating manufacturing capacity to deal with problems of oversupply. Sales and profits rose 11% (albeit flattered by rising materials prices), while volumes grew by around 15%. Management believe that they can improve margins and return on equity further, given higher utilisation rates and use of operating leverage.

China Mengniu Dairy delivered strong results in FY2017<sup>2</sup>, with accelerated revenue growth in the second half. Mengniu's brand-building efforts and football sponsorship has started to pay off, as it has increased market share and expanded margins. Last year, total revenue rose by 12% year-on-year, volumes increased by 9% and net profits reached a record high of RMB2.7 billion. Gross margins continued to improve from 31.4% in 2015, to 32.8% in 2016 and 35.2% in 2017.

## Early reformers show positive results

We would likely see sustained productivity improvement and higher returns from these restructured entities over time, if we consider the likes of **Wanhua Chemical, Gree Electric Appliances** and **CSPC Pharmaceutical** as encouraging case studies. These state-owned companies were early reformers and have been operating akin to private companies for more than a decade.

Established in 1998, Wanhua Chemical (formerly Yantai Wanhua Polyurethanes Co) is one of the world's largest producers of methylene diphenyl diisocyanate (MDI)<sup>3</sup>, with multiple overseas offices selling to more than 60 countries globally.

In 2005, reforms were implemented at the parent company, Wanhua Industrial Group. SASAC reduced its shareholding in the group to 60%, while at the same time 20% of the company was distributed to the management – providing alignment with minority shareholders – and another 20% to foreign investors. SASAC subsequently reduced its shareholding to 39%.

More recently, in June 2018, Wanhua Chemical announced that it would acquire its controlling shareholder, Wanhua Huagong, through an issuance of shares to the latter's five shareholders. After the acquisition, Wanhua Chemical's MDI capacity is expected to become the largest globally, overtaking current market leader, BASF.

In addition to ownership reform, Wanhua Chemical's management team supported market-based practices and provided commercial compensation schemes. Each divisional senior manager takes on responsibility for part of the business and is compensated accordingly.

Wanhua's long-term results have been impressive. Since listing on the Shanghai Stock Exchange in 2000, annual return on equity has averaged around 28%, while earnings per share has compounded at 27% over the same period.

Gree Electric Appliances, China's largest air-conditioner manufacturer, is another example of successful reform. In 1996, at the time of listing, parent company Gree Group (100% owned by SASAC) held 60% of the total share capital of Gree Electric. A series of rights issues, followed by a 2005 shareholder reform program, reduced the Group's ownership of Gree Electric to below 50%.

Concurrent to the shareholder reform program, Gree Electric introduced an incentive scheme which enabled management and technical staff to purchase shares at the prevailing net asset value if profits grew by a pre-determined annual growth rate. In FY05, FY06 and FY07, the hurdle rate was 20%, 10% and 10% respectively – actual realised profits growth for each corresponding fiscal year was 20%, 36% and 84%.

2 FY = fiscal year

3 MDI is a type of polyurethane that is used in a wide range of applications, from synthetic leather goods and textiles, to heat insulation materials for refrigerators and buildings exteriors.

## First State Stewart Asia – China Equities

Gree's success is often credited to its charismatic leader, Dong Mingzhu. Joining as an entry-level saleswoman in 1990, Dong proved to be an astute marketer and rose quickly through the ranks, eventually becoming chief executive officer in 2001 and chairwoman in 2011.

Over the past 15 years under Dong's tenure, Gree has delivered an average return on equity of around 28%, while earnings per share has grown by around 28% CAGR<sup>4</sup>. Dong continues to buy shares in the open market. Her personal net worth has multiplied along with Gree's market valuation.

Our final example is CSPC Pharmaceutical, which was owned by the state-owned Shijiazhuang Pharmaceutical Group (SPG). Listed in 1994, CSPC was one of the largest vitamin C and antibiotics manufacturers (classified as 'bulk pharmaceuticals') in China. Its results have been improving gradually and growth is likely to be reasonably visible over the next few years, as its core drug, "NBP" continues to take market share.

In 2007, the management of SPG along with Hony Capital, the private equity arm of Legend Holdings, executed a buy-out of SPG from the government and effectively turned the company into a private enterprise.

Following the shareholder reform, SPG pivoted away from the bulk pharmaceuticals segment, a low margin and cyclical business with little pricing power, and invested into research and development (R&D) for 'innovative drugs', largely in the form of being first to the China market with generic drugs or developing a new delivery mechanism for existing drugs in the China market.

In 2012, SPG injected all of its pharmaceutical manufacturing businesses, including "NBP", "Oulaining" and "Xuanning" – three of its top selling drugs today – into CSPC. "NBP", the largest contributor to profits due to its inclusion on China's National Reimbursement Drug List (NRDL), treats ischemic stroke and is patent-protected until 2023, while "Oulaining" treats dementia and "Xuanning" is used for the treatment of hypertension and angina.

After a series of partial share sales, Hony Capital fully exited CSPC in 2015. The chairman, Cai Dongchen now owns around 29% of CSPC, while the management own another 7%, indicating that the economic

interests of the management team are aligned with minority shareholders.

CSPC's research and development expenditure has grown by around 32% CAGR since the restructuring and the company has approximately 200 new products in the pipeline, including treatments for cardio-cerebrovascular, metabolic, oncology, psychiatry and neurology diseases.

Over the past three years, margins have improved as the product mix shifted from bulk pharmaceuticals to innovative drugs – innovative drugs now contribute around 70% of CSPC's business operations, up from 15-20% before the reform. Profits have grown at 29% CAGR and revenue at 8% CAGR.

### Outlook – on trade wars and tariffs

One of the key issues weighing on China (and the global economy) is the potential trade war with America. Tit-for-tat tariff

proposals have sent global equity markets into a tailspin. Market volatility has returned, reflecting the level of uncertainty on a range of possible outcomes.

China has long been accused by the US of unfair trading practices and of disadvantaging foreign firms in its home market. The US tariff list targets USD50 billion worth of goods covered by the "Made in China 2025"<sup>5</sup> strategy, in a bid to slow down China's supposed hegemony. China retaliated with a list of its own, striking tactically at farmers, as well as strategically-important industries in the US, such as airplanes and motor vehicles. As negotiations continue, investor sentiment has veered between optimism and doubt.

On the surface, it looks like China would be at greater risk from a trade war. At the end of 2017, Chinese exports reached a record high of USD2.3 trillion with a global surplus of USD423 billion – its surplus with the US alone was USD276 billion.

However, China's economy is much less dependent on exports than it used to be. As a result of rising incomes and efforts to rebalance the economy, domestic consumption is now the largest contributor to China's economic growth. The US-proposed 25% import duty on USD50 billion of Chinese goods is equivalent to just 0.1% of China's GDP and affects only 2.2% of China's total exports.

Although higher tariffs would undoubtedly hamper trade volumes, the extent of its impact is unclear. Today, products are made up of hundreds of components manufactured in factories all around the world. Goods are no longer simply made in one country and sold in another. American tariffs on Chinese goods – and vice versa – would probably lower trade volumes globally, not just in China; and result in dampened business confidence and capital expenditures in global markets.

4 Compound annual growth rate

5 In 2015, President Xi Jinping unveiled the "Made in China 2025" strategy, prioritising investments in smart technology and innovation-led industries in a bid to advance China's manufacturing sector and shift its economy forward. The strategy aims to focus manufacturing on higher value-added products and move away from the lower-quality/mass-quantity manufacturing of the past.

## First State China A Shares Fund

### Cumulative performance in USD net of fees (%)

	Since inception	5 Years	3 Years	1 Year	6 months	3 months
First State China A Shares Fund*	154.8	153.9	24.4	32.0	4.8	2.8
MSCI China A Onshore Index	26.8	32.4	-34.4	7.1	-8.6	-8.8


### Calendar year performance in USD (%)

	2017	2016	2015	2014	2013
First State China A Shares Fund*	45.7	-2.8	19.3	25.0	22.3
MSCI China A Onshore Index	20.3	-19.0	7.2	46.9	1.0

### Top 10 holdings (%)

	Sector	Fund
Yunnan Baiyao Group	Health Care	9.5
Wanhua Chemical Group	Materials	9.4
Tsingtao Brewery	Consumer Staples	9.2
Great Wall Motor Class H	Consumer Discretionary	5.2
Xinjiang Goldwind Science & Technology Class H	Industrials	4.7
Shanghai International Airport	Industrials	4.6
China South Publishing & Media Group	Consumer Discretionary	4.4
Lu Thai Textile	Consumer Discretionary	4.3
Anhui Heli	Industrials	4.1
Shandong Himile Mechanical Science & Technology	Industrials	3.9

### Sector breakdown (%)



Source: Lipper & First State Investments, Nav-Nav (USD total return) as at 31 May 2018.

\* The First State China A Shares Fund Class A FV (USD - Acc) - Inception date: 29 January 2010. Allocation percentage is rounded to the nearest one decimal place and the total allocation percentage may not add up to 100%. Past performance is not indicative of future performance. The First State China A Shares Fund is not available for investment by US persons. Fund information is being provided as an example of First States Investments' expertise in the strategy. Differences between fund-specific constraints or fees and those of a similarly managed mandate would affect performance results.

## First State China Growth Fund

### Cumulative performance in USD net of fees (%)

	Since inception	10 years	5 years	3 years	1 years	6 months	3 months
First State China Growth Fund*	1,827.2	126.1	71.0	33.7	40.4	12.8	2.3
MSCI China Index	549.7	68.9	75.3	22.7	30.9	5.6	-1.5


### Calendar year performance in USD (%)

	2017	2016	2015	2014	2013
First State China Growth Fund*	55.7	-3.2	-4.0	-2.8	21.4
MSCI China Index	54.1	1.1	-7.6	8.3	4.0

### Top ten holdings (%)

	Sector	Fund
Tencent	Information Technology	6.5
CSPC Pharmaceutical Group	Health Care	5.7
China Merchants Bank Class H	Financials	5.1
ENN Energy	Utilities	5.0
China Mengniu Dairy	Consumer Staples	3.6
AAC Technologies	Information Technology	3.6
Midea Group	Consumer Discretionary	3.4
China Taiping Insurance	Financials	3.4
Mint Group Limited	Consumer Discretionary	3.4
Shanghai International Airport	Industrials	3.3

### Sector breakdown (%)



Source: Lipper & First State Investments, Nav-Nav (USD total return) as at 31 May 2018. Allocation percentage is rounded to the nearest one decimal place and the total allocation percentage may not add up to 100%.

\* The First State China Growth Fund Class I (USD - Acc) - Inception date: 17 August 1999. Past performance is not indicative of future performance. The First State China A Shares Fund is not available for investment by US persons. Fund information is being provided as an example of First States Investments' expertise in the strategy. Differences between fund-specific constraints or fees and those of a similarly managed mandate would affect performance results.

## **Important Information**

This material is solely for the attention of institutional, professional, qualified or sophisticated investors and distributors who qualify as qualified purchasers under the Investment Company Act of 1940 and as accredited investors under Rule 501 of SEC Regulation D under the US Securities Act of 1933. It is not to be distributed to the general public, private customers or retail investors in any jurisdiction whatsoever.

This presentation is issued by First State Investments (US) LLC (“FSI” or “First State Investments”). The information included within this presentation is furnished on a confidential basis and should not be copied, reproduced or redistributed without the prior written consent of FSI or any of its affiliates. First State Investments funds are not registered for sale in the US and this document is not an offer for sale of funds to US persons (as such term is used in Regulation S promulgated under the 1933 Act). Fund-specific information has been provided to illustrate First State Investments’ expertise in the strategy.

Differences between fund-specific constraints or fees and those of a similarly managed mandate would affect performance results. This material is provided for information purposes only and does not constitute a recommendation, a solicitation, an offer, an advice or an invitation to purchase or sell any fund and should in no case be interpreted as such. Any investment with First State Investments should form part of a diversified portfolio and be considered a long term investment. Prospective investors should be aware that returns over the short term may not match potential long term returns. Investors should always seek independent financial advice before making any investment decision. The value of an investment and any income from it may go down as well as up. An investor may not get back the amount invested and past performance information is not a guide to future performance, which is not guaranteed.

Certain statements, estimates, and projections in this document may be forward-looking statements. These forward-looking statements are based upon First State Investments’ current assumptions and beliefs, in light of currently available information, but involve known and unknown risks and uncertainties. Actual actions or results may differ materially from those discussed. Readers are cautioned not to place undue reliance on these forward-looking statements. There is no certainty that current conditions will last, and First State Investments undertakes no obligation to publicly update any forwardlooking statement.

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE PERFORMANCE.

Reference to the names of each company mentioned in this communication is merely for explaining the investment strategy, and should not be construed as investment advice or investment recommendation of those companies. Companies mentioned herein may or may not form part of the holdings of FSI. The comparative benchmarks or indices referred to herein are for illustrative and comparison purposes only, may not be available for direct investment, are unmanaged, assume reinvestment of income, and have limitations when used for comparison or other purposes because they may have volatility, credit, or other material characteristics (such as number and types of securities) that are different from the funds managed by First State Investments. Apart from First State Investments, neither the Commonwealth Bank of Australia (the “Bank”) nor any of its subsidiaries are responsible for any statement or information contained in this document. Neither the Bank nor any of its subsidiaries guarantee the performance of any fund or the repayment of capital by any fund. Investments in a fund are not deposits or other liabilities of the Bank or its subsidiaries, and the fund is subject to investment risk, including loss of income and capital invested.

For more information please visit [www.firststateinvestments.com](http://www.firststateinvestments.com). Telephone calls with FSI may be recorded.